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The Impact of Social Contexts
in Testing for Alpha-1 Antitrypsin Deficiency:
The Roles of Physicians and Others
Robert Klitzman
Aims: To elucidate psychosocial and ethical issues faced by adults at risk for alpha-1 antitrypsin deficiency
(AATD) that have received little attention. Methods: Eleven individuals with AATD were interviewed in detail
for 2 hours each. Results: Several specific aspects of AATD created critical, socially dynamic issues that shaped
the patients’ responses. The disease being relatively newly discovered, physicians do not know much about it
and thus often do not consider or recommend testing for it. Hence, patients who may benefit from diagnosis and
treatment are not always diagnosed. General practitioners, when they do diagnose patients, often refer them to
specialists and thus remain inexperienced in treating the disorder. As a result, many individuals, too, remain
unaware of this disease in their families and thus do not consider mentioning its possibility to doctors or family
members. Thus, intrafamilial disclosures by patients become critical. Patients may be shocked and upset at
diagnosis, as they might possibly already have transmitted the mutation to offspring, which further impedes
disclosure to family members. Conclusions: These issues highlight how patients’ interactions with doctors and
others concerning genetics are critical, and need to be further explored and addressed. Several aspects of
physician education and practice (e.g., regarding disclosures to at-risk family members) need to be improved.
Introduction
The literature on ethical, legal, and social issues in ge-netics has tended to focus on several disorders, and paid
less attention to others that might be important in under-
standing the full implications of the rapidly expanding use
of genetic tests. Researchers have identified genes for thou-
sands of disorders, prompting testing for many of these con-
ditions through clinicians and direct-to-consumer marketing
on the internet. An important case in point is alpha-1 anti-
trypsin deficiency (AATD), the only disease for which the
Equal Employment Opportunity Commission ruled that ge-
netic discrimination has occurred (Oveson and Yarborough,
2001; Jones and Smith, 2003).
For several other adult-onset diseases, studies have explored
how patients make decisions about testing—for example, for
Huntington’s disease (Klitzman et al., 2007a, 2007b, 2007c),
breast cancer ( Jacobsen et al., 1997; d’Agincourt-Canning,
2006), and hereditary nonpolyposis colorectal cancer (Aktan-
Collan et al., 2000; Hadley et al., 2003). AATD may resemble,
and=or differ from, these other conditions in critical ways—
such as the timing and extent of clinical presentation, severity of
symptoms, means of diagnosis, patterns of inheritance, and ge-
netic expression—all of which can affect patient and health care
provider making decisions about testing, treatment, and care.
AATD, a genetic disorder caused by defective production
of alpha-1 antitrypsin, was discovered in 1963 (Laurel and
Eriksson, 1963). This condition is autosomal codominant and
affects the liver and lungs. Very low levels of antitrypsin pre-
dispose to the development of emphysema, which, if left un-
treated, can lead to early death. Individuals with phenotypes
for severe deficiency (PiZZ or PiSZ) are also susceptible to liver
disease and cirrhosis. Liver transplantation may be necessary in
severe cases. Early detection of the disorder through genetic
testing enables initiation of organ replacement, avoidance of
environmental factors that can exacerbate illness (e.g., smoking
and certain pollutants), and participation in genetic counseling
and family planning programs (Hogarth and Rachelefsky,
2008).
In the United States, approximately 1=5000 individuals or
about 60,000 individuals have phenotypes for severe AATD
(Browne et al., 1996), yet its symptoms have been diagnosed in
only about 5% of cases (Campos et al., 2005). Worldwide,
approximately 10,000 patients (about 5000 in the United
States) now receive treatment for this disorder (Stolk et al.,
2006). Thus, in the United States, over 80% of patients who
would benefit from treatment do not receive it. Many physi-
cians remain unaware of problems caused by AATD (Stolk,
2005). Diagnosis itself can cause depression and anxiety. A
study that screened Swedish neonates found that mothers of
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AATD children had significantly more anxiety, at least in the
short term, than those of matched controls (Sveger et al., 1999;
Sveger and Thelin, 2000). The World Health Organization
(2006), The American Thoracic Society, and the European
Respiratory Society have issued recommendations (ranked as
to relative degree of importance) that in Europe and North
America, given the relatively high prevalence of the disease,
physicians should test patients, including those with em-
physema, chronic obstructive pulmonary disease, untreatable
asthma with air flow obstruction, and unexplained liver dis-
ease, and siblings and relatives of patients with AATD
(American Thoracic Society, 2003; Hogarth and Rachelefsky,
2008). However, it is not known how far these recommen-
dations are effective in improving the situation.
Despite the increased attention given to AATD since its
discovery, between 1968 and 2003 diagnoses of the disease by
physicians did not improve, and in fact the length of time
between symptoms and diagnosis increased (Campos et al.,
2005). Moreover, patients often report insufficient genetic
counseling (Sveger et al., 1999; Stolk, 2005).
Thus, critical questions arise about specific obstacles to
earlier and more frequent testing of patients at risk. In general,
physicians have limited understanding of genetics (Menasha
et al., 2000; Sifri et al., 2003; Wideroff et al., 2003). With other
diseases, communication between physicians and patients is
often deficient as well (Klitzman, 2006a, 2006b, 2008). In the
case of Huntington’s disease (Klitzman et al., 2007b) and HIV-
AIDS (Klitzman and Bayer, 2003), critical obstacles also exist
to disclosure of diagnoses by patients to others who may be at
risk and to health care providers. Indeed, among individuals
recruited through an AATD patient organization, one-third of
whom requested a testing kit and returned it, and about half
(56%) of whom also then completed a questionnaire, most
said they planned to tell family members, though not all (only
82.9% of homozygotes for mutations, and 59.9% of carriers)
would tell their physician (Strange et al., 2004). However, the
number of individuals who actually did tell their family
members was not ascertained. Moreover, this subsample of
respondents is unusual in already being connected to a patient
advocacy group, and being motivated to both undergo testing
and complete the questionnaire. But disclosures to both
family and providers may still be suboptimal.
Clearly, many psychological, social, and ethical issues faced
by adult patients at risk for AATD have received little or no
attention—for example, concerning whether, when, and how
physicians and patients end up deciding to pursue testing
(how they view and make these decisions, and what addi-
tional factors, may be involved), and how patients decide
whether, when, what, and to whom to disclose their test re-
sults. Moreover, much of the work above has been done in
Scandinavia, not in the United States, and systems of health
care in these two parts of the world vary radically (World
Health Organization, 2006). In Sweden, the condition is much
more common (about 1=1500). Universal health coverage may
dramatically alter attitudes and approaches toward making
decisions about testing, disclosure, and health care among
both providers and patients.
From a theoretical perspective, the Health Belief Model
suggests that perceived susceptibility, disease severity, and
costs and benefits may affect an individual’s health behaviors
(Rosenstock et al., 1988). Such a model has been applied to
decisions about testing for other genetic diseases (Klitzman
et al., 2007b), but has not yet been examined with regard to
AATD. The Stages of Change Model (Prochaska et al., 1992)
suggests that individuals go from being unaware and un-
engaged to making decisions about whether to follow a health
behavior (e.g., testing) or not. This model has also been ap-
plied to other diseases (Klitzman et al., 2007b), but not AATD,
where it may be relevant, too.
In short, it is important to examine the processes through
which individuals at risk for AATD decide whether to un-
dergo testing, when to disclose to family members and others,
and what roles physicians may play in these decisions—for
example, what obstacles are involved, how they operate, and
what can be done to address them.
Materials and Methods
Sample
Eleven individuals with AATD (seven women and four
men) were interviewed in detail for 2 hours each. Table 1
provides background information on the participants, in-
cluding employment status, years since diagnosis of the dis-
order, and treatment taken.
Information about the study was distributed through an
AATD clinic, an AATD organization, an AATD newsletter,
and word of mouth. Individuals interested in participating
contacted the principal investigator (PI), who conducted
Table 1. Background Info on Alpha-1 Antitrypsin Deficiency Interviewees
Treatment
ID # Sex Age Years since diagnosis Employment status Prolastin Other
1 F 57 12 Unemployed Yes
2 F 59 4 Professional Yes
3 F 48 10 Unemployed Yes Double lung transplant
4 M 61 11 Professional Yes
5 F 61 5 Professional Yes
6 F 65 15 Professional Yes
7 F 70 4 Professional Yes
8 F 59 7 Professional Yes Portable oxygen
9 M 59 23 Professional Yes
10 M 54 12 Professional Yes
11 M 71 4½ Professional Yes
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a confidential in-depth semistructured interview with each
concerning experiences of having, or being at risks for, AATD.
Interviews were conducted in the PI’s office. The Columbia
University Department of Psychiatry Institutional Review
Board approved the study, and all participants gave informed
consent. Table 2 presents sample questions from the semi-
structured interview guide. We sought to obtain detailed de-
scriptions of the participants’ views and decisions concerning
testing and related issues.
On theoretical grounds, Geertz (1973) has advocated
studying aspects of individuals’ lives and social situations by
trying to understand their experiences and drawing on their
own words and perspectives to obtain a ‘‘thick description,’’
rather than by imposing external theoretical structures.
Hence, we used qualitative methods to fully understand the
various factors and issues that may be involved in genetic
testing decisions.
In our methods, we adapted elements from grounded
theory, as described by Strauss and Corbin (1990), because we
were interested in understanding a complex social process.
We have used these methods in several other studies in-
volving genetics (Klitzman et al., 2007a, 2007b, 2007c) and
other aspects of health behavior and doctor-patient relation-
ships and communications (Klitzman et al., 2006a, 2006b).
Specifically, grounded theory involves both inductive and
deductive thinking, building inductively from the data to an
understanding of themes and patterns within the data, and
deductively drawing on frameworks from previous research
and theories. For example, interviewees introduced topics
such as interactions with providers, which were then explored
further in these and other interviews. Our approach was in-
formed constant comparison, in which data from different in-
dividuals were compared for similarities and differences to
see whether these suggested hypotheses. Transcriptions and
initial analyses of interviews were done during the period in
which the interviews were being conducted and helped guide
subsequent interviews. Interviews were conducted until
‘‘saturation’’ was reached (i.e., ‘‘the point at which no new
information or themes are observed in the data’’) (Strauss and
Corbin, 1990; Guest et al., 2006).
Once the full set of interviews was completed, subsequent
analyses were conducted in two phases, primarily by the PI
together with a research assistant who had social science
training. At several points during the analysis, we also
received input from another senior expert in qualitative re-
search. In phase one of the coding process, the PI and the
research assistant independently examined a subset of inter-
views to assess factors that shaped participants’ experiences,
identifying categories of recurrent themes and issues that
were subsequently given codes. These two coders assessed
similarities and differences between participants, examining
themes and categories that emerged, ranges of variation
within categories, and variables that may be involved. They
systematically coded blocks of test to assign ‘‘core’’ codes or
categories. While reading the interviews, a topic name (code)
was inserted beside each excerpt of the interview to indicate
the themes being discussed. The coders then worked together
to reconcile their independently developed coding schemes
into a single scheme, developing a coding manual and ex-
amining areas of disagreement until reaching consensus be-
tween them (i.e., when each coder’s view of a phenomenon or
theme raised by a participant was reconciled into a coherent
understanding of it). New themes that did not fit into the
original coding framework were discussed, and modifications
were made in the manual when deemed appropriate.
In the next phase of the analysis, the thematic categories
were subdivided into secondary themes or subcodes, and
then refined and merged, when suggested by associations
or overlap in the data. Codes and subcodes were then used in
analysis of all of the interviews. Major codes (or categories) of
text included, for example, occasions when providers gave
input about the disease, and when patients informed family
members. Subcodes (or subthemes) were conceptual and
thematic subdivisions of these larger categories and included
reactions and behaviors of physicians once they diagnosed
patients (e.g., referrals to specialists, discussions with patients
or family members). To ensure coding reliability, the two
coders analyzed all interviews. Areas of disagreement were
examined to reach consensus. To ensure trustworthiness, an
external senior qualitative researcher was frequently con-
sulted at multiple points and the data triangulated with
existing literature on other genetically associated diseases.
These data also have a certain face validity that further sub-
stantiates their trustworthiness. We have presented below
text from the interviews to allow readers to judge these data
for themselves as well.
Results
As illustrated in Figure 1, several key unique characteristics
of AATD shaped the decisions knowledge and behaviors of
individuals, which then proved interrelated, forming a com-
plex, interdynamic system that contributed to undertesting
and underdiagnosis of the disease.
The following are such characteristics of the disease: First,
it is relatively rare. Second, it is an autosomal recessive
condition, and—unique from several other genetic diseases—
heterozygotes for the mutation, if they smoke, can potentially
have symptoms (though not as severely as those who are
homozygote for the mutation) that may or may not be related
to the condition. Third, enzyme replacement is possible.
As the disease is uncommon and its genetic basis relatively
new and hence less known, doctors and health care workers
(HCWs) do not know much about AATD. This leads to un-
dertesting and underdiagnosis of the disease, as in the fol-
lowing instance.
‘‘I saw 20 doctors; none of them tested me for Alpha, or
knew what it was. I still come across doctors who don’t know
what it is. They ask me, ‘Any medical history?’ I say I’ve got
Alpha One. ‘What is that?’ ’’ (Table 1, ID #3)
These patients felt that certain types of specialists, in par-
ticular, should know about AATD, but often do not.
Table 2. Semistructured Interview Guide
(Sample Questions)
When did you first find out you were at risk of Alpha,
and what was your reaction at that time?
How did you find out you were at risk?
Have you undergone genetic testing for Alpha? Why
or why not?
How did you make this decision?
Whom have you told or not told about having=being
at risk of the disease? How did you make these decisions?
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‘‘Any pediatrician, pulmonary doctor, or doctor that deals
with asthma, should be up to date and fully aware of this
disease.’’ (Table 1, ID #3)
Yet, the rareness of the disease contributes to doctors
being less aware of it. This problem may also arise for other
relatively rare disorders for which single-point mutations are
nevertheless found.
‘‘If a disease has been around for many years, everybody
knows about it. Alpha is so new and rare. Doctors don’t know
about it, therefore it’s missed. I went back to two of those
doctors to get it off my chest. I expected, ‘I’m sorry, I wish I
had known, or had more knowledge.’ But one made a smart
remark. I called him an asshole.’’ (Table 1, ID #3)
Doctors may know the name of the disease, but little else, if
anything, about it.
‘‘I liked one doctor a lot, but when she had my file she
obviously knew the term, but not really a whole lot about it.
Nor should she. I was hospitalized for pneumonia a couple of
years ago, and was close to my main Alpha doctor, but other
residents would come in. One young intern is going to be an
excellent doctor. She said, ‘You’re my first Alpha, I read all
about this in medical school.’ I look pretty much like every-
one else, except if you see my x-rays.’’ (Table 1, ID #9)
As a result, ‘‘There are a lot of people who know more
about this than the doctors do,’’ (Table 1, ID #9), which can in
turn create stresses and strains in receiving treatments and
interacting with providers.
Providers’ low knowledge of a disease, especially a rela-
tively unusual one, can also lead them to dispense inaccurate
information about testing and other aspects of the illness.
Without much understanding, physicians may give patients
incorrect prognoses and advice.
‘‘Some Alphas are mad that their doctor didn’t know squat,
and just told them they’re going to die. One person was di-
agnosed early on, in the early 80s, and told not to exercise:
‘You only have so much function left. Don’t use it up with
exercise’—which turns out is exactly the wrong advice. He got
a lung transplant 9 years ago, and died 2 years ago, but was
told he was going to die in ’81!’’ (Table 1, ID #10)
Owing to lack of knowledge about the condition, doctors
do not test for it as often as they should. Often, only the pa-
tient’s persistence prompts eventual assessment and testing.
Doctors may at first miss the diagnosis and later send the
patient to specialists. Yet such secondary or tertiary referrals
may serve to keep knowledge or experience about AATD low
among general internists and other less specialized doctors,
furthering a self-perpetuating cycle.
‘‘Before I caught Alpha-1, when I just had plain old em-
physema, I was tested in my local hospital, which is pretty
good. But did the respiratory therapist or doctor say, ‘Maybe
you should test for Alpha’? No. I would think that would have
been the first thing they’d say. But that was back in the 80s. I
don’t know what they knew. I was seeing a family practice
doctor. I said, ‘I need to see you because I’m not getting any
better.’ He finally did diagnose me, but then got me mad
because he didn’t want to see me as a patient. He sent me to
New York, because he didn’t have any Alpha patients, and
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FIG. 1. Interacting themes concerning characteristics of AATD and their implications for providers and patients.
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Referral to specialists may also require further travel and
cause logistical difficulties for patients.
‘‘It turns out, looking back, that was the exact right thing for
him to do. But at the time, I was upset. I didn’t want to come to
New York. It’s a pain in the ass.’’ (Table 1, ID #10)
Patients may feel frustrated, not understanding the need
for a referral, and realizing only in retrospect that such referral
may be the best. They may see only the final outcome as
justifying the extra effort. For rare diseases, reliance on spe-
cialists may enhance the care, but it would minimize other
physicians’ experience in treating future patients and the
motivation to gain such experience.
Family histories of the diagnosis are also often not known.
The presence of the disease may not be recognized because of
poor prior diagnoses, or because a family history is commu-
nicated poorly, if at all. Moreover, relatives may have had
undiagnosed AATD.
‘‘My father’s sisters and brothers could have had it. A cousin
died at 35 of emphysema. At that time, they didn’t know what
Alpha was, so it could have been.’’ (Table 1, ID #3)
In fact, known only since 1963, AATD was often missed
before that.
‘‘My cousin’s father was possibly a carrier. He was turned
down during World War II. I think it’s because he had asthma
or something like that. Alpha wasn’t discovered until 1963.’’
(Table 1, ID #8)
Indeed, several participants said they were the first in their
family to be diagnosed—which may frequently be the case for
codominant or recessive disorders. Hence, entry into the Al-
pha community may be further impeded or delayed.
Over time, cultural and familial norms and taboos about
discussing diagnoses have also shifted. In the past, more ret-
icence reigned. On the other hand, the hereditary nature of the
disease in and of itself could help prompt disclosure. One
woman said about the major differences between genetic and
other diseases:
‘‘I wonder if my grandparents had breathing problems. My
father’s mother died when he was very young. They don’t
know what she died from. People didn’t talk about things
then.’’ (Table 1, ID #5)
Yet patients may first learn about their own risk through
relatives’—even offspring’s—experiences. Since physicians
may have little clinical exposure to the disease, they may not
apply their past-acquired factual knowledge in clinical contexts.
‘‘I had been sick for a while, not responding to antibiotics.
Then, my son came for Christmas and had pneumonia, which
he’s been prone to since a young child. He was on an antibiotic.
But I sent him down to my doctor, and made him promise to
have tests done when he got back to his own home. He did that
and a couple of months later was sick again. I asked him, ‘Did
you ever see your doctor?’ He said, ‘Well, yeah, as a matter of
fact, I have something with a missing enzyme. They said it’s
not a concern right now.’ A month or so later, my family doctor
asked me if he had had testing done. I said, ‘Yeah, they told
him he had some kind of missing enzyme,’ and the light bulb
went on for my doctor. He said, ‘Alpha Antitrypsin! My God,
I’ll bet that’s what you have!’ ’’ (Table 1, ID #6)
Yet a doctor may not tell a patient to disclose the diagnosis
to at-risk family members.
‘‘My son’s doctor did not say, ‘You should tell your parents
to get themselves checked out.’ It was a gift from the gods that
the scenario played out for me the way it did. If I hadn’t asked,
I wouldn’t have found out. I don’t know that he even told
him it was genetic, just that it was an enzyme deficiency.’’
(Table 1, ID #6)
Poor communication may have resulted, too, from avoid-
ance or denial concerning the disease.
‘‘My son is in tremendous denial about this. He’s a heavy
smoker.’’ (Table 1, ID #6)
Disclosure within families is thus particularly important,
but may encounter significant obstacles. Family members
may also be estranged. If the condition were not genetic, some
felt they would not have to communicate with, or tell, these
other individuals at all.
‘‘You have to speak to, and reach out to family members
that you probably wouldn’t speak to.… If it wasn’t genetic,
you wouldn’t bother even telling them.’’ (Table 1, ID #3)
Yet, diagnosis with a potentially lethal disease can also
shock relatives, impeding their disclosure of the illness to other
relatives.
‘‘I felt depressed, scared, told I have a lethal disease—that
more than likely, I will not live a normal life span.’’ (Table 1,
ID #10)
Many are shocked, too, suddenly confronted with complex
information about a disease they had never heard of.
‘‘We were numb. The doctor taped the meeting—though
we didn’t want to let him. But we went back to the house, and
sat down and listened to it several times, and tried to figure
out what it was all about.’’ (Table 1, ID #8)
The unexpected nature of the process of diagnosis—the fact
that patients are not psychologically prepared and genetic
counseling may not have been given—can lead to confusion,
which then prevents patients from disclosing this information
to other relatives who may also be at risk and could poten-
tially benefit from genetic testing and treatment.
When diagnosed, individuals are suddenly confronted by a
large amount of new, complex, and threatening information
about diagnosis, prognosis, and treatment, including often
seeing further patients with more advanced disease.
‘‘I went to a specialist and saw all these gray people car-
rying these oxygen canisters. I was really knocked out. It took
me a year to really get back. In my town, I know how to deal
with everything. Not as stressful as going to a strange place in
a wheelchair, because it’s hard to walk. And with a sinus
infection I can’t do anything. Once you get used to it, it isn’t
as bad. But I never thought this way. When you’re in an un-
familiar place and can’t breathe, it’s more stressful.’’ (Table 1,
ID #8)
Nonetheless, the diagnosis can be a relief as it provides an
answer to the patient’s problem and can lead to initiation of
beneficial prevention and treatment.
‘‘I was so pleased to get an actual diagnosis that match-
ed, because I didn’t feel I fit emphysema … I felt better
knowing.’’ (Table 1, ID #2)
Questions arose as to whether doctors should encourage
patients to have family members tested and, if so, when, how,
and to what degree. Some felt that physicians should indeed
do so. Yet the question remained, to what degree.
‘‘It was up to the doctor … to either write it down for [the
patient] or tell him: ‘This is what you have. You are a carrier.
You’ve got this gene from one of your parents. Have your
parents tested.’ ’’ (Table 1, ID #5)
Thus, doctors do not always communicate about the im-
portance of disclosure and testing issues. This patient may have
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been told to tell his parents, but for various reasons may not
have either fully heard or been able to follow the advice.
Discussion
These data show how several specific aspects of AATD—
primarily its rareness, and the resemblance of its symptoms to
more common diseases such as asthma or chronic obstructive
pulmonary disease—lead to circumstances that profoundly
shape the responses of health care providers and patients.
Specifically, its newness leads to physicians not knowing
much about it, and thus often not considering or ordering
genetic tests for it. Consequently, patients who may benefit
from diagnosis and treatment are not tested or diagnosed.
Moreover, primary providers, when they do diagnose a pa-
tient, then often refer that patient to a specialist for treatment.
General practitioners thus do not acquire the added experi-
ence that might be helpful.
All these factors contribute to individuals being unaware
of this disease in their family and thus not mentioning the
possibility of the diagnosis to their doctors. Disclosures by
patients to other family members thus becomes extremely
important. Yet physicians may or may not tell patients, when
diagnosed, to inform other kin. Newly tested patients may be
shocked and upset (i.e., anxious and depressed) at being di-
agnosed with a potentially fatal genetic disease, the mutation
for which they might already have passed onto their children
or even grandchildren. Treatment is costly, and organ trans-
plants may be needed, which are difficult to obtain. These
may further impede disclosure within a family.
Thus, providers and patients form a vicious cycle—a com-
plex set of positive feedback loops that impede testing and
subsequent treatment. Low knowledge among both providers
and patients can be mutually reinforcing, and hamper dis-
course and discussions between patients on the one hand and
providers and at-risk family members on the other.
To alter these dynamics requires careful efforts to improve
knowledge and behavior of patients and providers. At first
glance, this problem may seem inevitable, and difficult
to remedy except through broad population-based screening.
Yet increased awareness of these difficulties among medical
educators and providers may help ameliorate it. This study
thus highlights the importance of examining these complex
social interactions and dynamics—for example, between pro-
viders and patients—involved in the testing and disclosure of
genetic diseases.
From a theoretical perspective, these data highlight the de-
grees to which social interactions shape perceived awareness
and susceptibility to a disease—key components of the Health
Belief Model and Stages of Change Model, respectively. Stages
of change, going from being unaware to being engaged in
making a decision, are very much molded by dynamic social
processes, with social inputs from providers, family members,
and others. One at-risk individual can tell others, who can then
inform more individuals. Thus, it is critical that providers un-
derstand and appreciate these interactions. At the same time,
these data underscore both the limitations of these two rational
choice models and the need to develop more nuanced frame-
works that examine and take into account these complex social
systems and dynamic processes. For example, various char-
acteristics of immediate and extended families as social entities
may affect whether, when, what, and how information is
communicated within them. These characteristics may prove
critical in influencing whether, when, and to what extent
individuals become aware of their susceptibility to genetic
disease.
The fact that these dynamics and characteristics of this
genetic disease shape the specific issues that arise has critical
implications for other genetic tests being pursued. Indeed,
mutations may in fact well be identified disproportionately
for rare versus more common diseases.
Genetic research may also lead to the identification and la-
beling of other new and rare diseases, and possibly of entirely
new diagnostic categories and disorders. Indeed, in the past,
nosologies have been altered by technological interventions
that permit more precise and sophisticated differentiation be-
tween disease states that were formerly lumped together. Such
other new disorders will pose similar challenges for the edu-
cation of both medical trainees and established providers, and
for clinical practice. Practitioners will need education to deal
with increasing complex decisions regarding testing, counsel-
ing, and disclosure. Physicians and medical educators need to
give more attention to addressing whether, how, and when
physicians and patients do or do not interact and communicate
concerning disclosures of genetic diagnoses to family members
who may also be at risk. Yet, here, ethical questions and ten-
sions arise. For example, patients may not be in touch with at-
risk family members. Patients may want to tell children who
are cognitively or emotionally too immature to comprehend or
handle the information adequately.
Patients may also want to arrange to test family members.
But these relatives may also be too young or unable to fully
respond to the information. Alternatively, physicians may
suggest in passing that family members be tested, but not
sufficiently follow-up or encourage them to be effective. Doc-
tors and other health care providers need to be fully prepared
to deal with these issues and be comfortable doing so. Physi-
cians may want to refer patients to genetic counselors to handle
these issues. But, unfortunately, there are only a little over 2000
genetic counselors in the United States (American Board of
Genetic Counseling, 2008), not all of whom are working at any
one time. Hence, physicians need to be able to provide coun-
seling information. Fortunately, AATD follows fairly straight-
forward Mendelian principles.
In general, physicians lack the training and ability to deal
with such uncertainties and communicate them to patients in
an effective way—even to the extent of not knowing whether to
use verbal or numerical approaches (and if numerical, per-
centages vs. proportions). HCWs may assign similar quanti-
tative probabilities to qualitative descriptions of odds but differ
from patients in interpreting these terms (e.g., ‘‘likely’’ vs.
‘‘unlikely’’) (Kong et al., 1986). Patients may assess rates dif-
ferently than proportions (Grimes and Snively, 1999) and be
affected by the order in which risks and benefits are presented
(Bergus et al., 2002). Medical education thus needs to be better
prepared to handle these issues.
The burgeoning availability of genetic tests and the arrival
of pharmacogenomics and direct-to-consumer marketing of
genetic tests makes these issues even more critical. Patients
and providers will increasingly need to deal with problems
related to testing, diagnosis, disclosure, and testing of other
family members, overcoming barriers that may exist. Physi-
cians and other HCWs will no doubt need to assume some
functions of genetic counselors, though at the moment they
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generally lack the necessary training to optimally do so.
Moreover, major challenges exist, since even with training,
physicians are not now reimbursed for such time-intensive
counseling. Hence, policy makers need to consider how to
address these systemic gaps—that is, whether to encourage or
mandate reimbursement for these functions. This study thus
has important policy implications as well.
These data indicate, too, the need for further research on
these and other key aspects of genetic disorders. Though rare,
and therefore often underresearched, such diseases serve as
powerful and important precedents for future genetic assays.
These data highlight the need to ensure that HCWs, patients,
and their families are adequately prepared to confront the
resultant challenges ahead.
In sum, physicians play critical roles, particularly when
dealing with rare genetic diseases, and may need more train-
ing to handle the complex issues that arise. Given the shortage
of genetic counselors, insurance companies need to reconsider
their current reimbursement policies to be able to address the
need for appropriate provider-patient interactions concerning
testing and disclosure. Genetic testing involves not only a
single patient at a time, but his or her family members who
may be at risk as well. Given the importance of early treat-
ment for many conditions, genetic tests for these will certainly
be developed. Failure to address disclosure may mean that
patients fail to inform at-risk family members, who may as a
result end up getting treatment too late, if at all. But to address
these issues will take time, and resources (e.g., appropriate
reimbursement) that will need to be established. Such efforts
are critical, however, for disease prevention and treatment.
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